27.01.2011 • News

Ranbaxy CEO Omesh Sethi Quits

Ranbaxy Laboratories, India's top drugmaker, said on Thursday its chief financial officer had resigned, the third top official to quit after Japan's Daiichi Sankyo took majority control.

The company, with annual sales of about $1.7 billion, did not give a reason for Omesh Sethi's resignation but said it was effective Jan. 25.

Shares in Ranbaxy, which the market values at about $5 billion, fell as much as 1.7 percent to 554.15 rupees in a subdued Mumbai market.

Sethi's exit comes less than six months after then chief executive Atul Sobti left citing a rift in strategy.

Daiichi had bought the holdings of Chairman and CEO Malvinder Singh and his family in 2008 and later made an open offer, in a deal valued at $5.4 billion, giving the Japanese No.3 drugmaker a launch pad to expand its generic offerings.Singh stepped down from the company in 2009.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.